Apogee Therapeutics (NASDAQ:APGE) Announces Quarterly Earnings Results

Apogee Therapeutics (NASDAQ:APGE) posted its quarterly earnings data on Monday. The company reported ($0.60) EPS for the quarter, meeting analysts’ consensus estimates of ($0.60), Yahoo Finance reports.

Apogee Therapeutics Stock Performance

APGE stock opened at $44.41 on Wednesday. The firm has a 50 day simple moving average of $43.02 and a 200 day simple moving average of $47.60. Apogee Therapeutics has a 52 week low of $14.19 and a 52 week high of $72.29. The stock has a market cap of $2.60 billion and a P/E ratio of -8.46.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on APGE shares. Wedbush restated an “outperform” rating and set a $87.00 price target on shares of Apogee Therapeutics in a report on Monday, May 13th. Bank of America started coverage on shares of Apogee Therapeutics in a research report on Friday, May 10th. They set a “buy” rating and a $80.00 price objective on the stock. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat, Apogee Therapeutics currently has an average rating of “Buy” and an average target price of $73.00.

Insider Buying and Selling at Apogee Therapeutics

In related news, insider Carl Dambkowski sold 5,995 shares of the stock in a transaction on Wednesday, July 3rd. The stock was sold at an average price of $37.60, for a total transaction of $225,412.00. Following the completion of the sale, the insider now directly owns 294,793 shares in the company, valued at $11,084,216.80. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. In related news, CEO Michael Thomas Henderson sold 40,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 7th. The shares were sold at an average price of $40.62, for a total transaction of $1,624,800.00. Following the transaction, the chief executive officer now owns 1,434,487 shares of the company’s stock, valued at $58,268,861.94. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Carl Dambkowski sold 5,995 shares of Apogee Therapeutics stock in a transaction that occurred on Wednesday, July 3rd. The shares were sold at an average price of $37.60, for a total transaction of $225,412.00. Following the completion of the sale, the insider now owns 294,793 shares of the company’s stock, valued at $11,084,216.80. The disclosure for this sale can be found here. In the last quarter, insiders have sold 68,330 shares of company stock worth $2,707,426. 36.10% of the stock is currently owned by company insiders.

About Apogee Therapeutics

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.